A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.

The gene therapy, which was acquired by Novartis in 2023, is also being tested in a separate Phase I/II trial of pediatric patients.

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

Federal immigration enforcement action may be winding down, but healthcare professionals say the "collective trauma" ICE inflicted on the community will be long lasting.

Distance, lack of coverage, and mistrust have limited Indigenous patients' access to basic and advanced medicine, but cancer centers are embracing strategies to change that.

The company is expecting additional readouts this year from studies of cancer vaccine intismeran autogene, which is being tested in late-stage trials.

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

The firm is developing RNAi drugs to treat neurological diseases by silencing genes in the brain, the first of which it will nominate this year.

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

The company is continuing to prepare for a second half rollout of anito-cel if it is approved by the FDA.

Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 versus the same periods in 2024.

The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at lower doses in a Phase I trial.

Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 billion in Q4 2025 revenue.

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi, or combining both.

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion in revenue, respectively.

The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology portfolio increased 9 percent year over year.

The firm missed Wall Street Q4 revenue estimates but assured steady growth as it plans for Keytruda's patent expirations, a deadline it hopes to hold off a bit longer.

CIRM will fund validation awards to bring therapies to human trials and innovation awards to those that "push the boundaries" of platform approaches.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat genetic hearing loss.

Three blood cancer organizations have appealed a NICE draft guidance, which could make the therapy unavailable for mantle cell lymphoma patients.

The nonprofit biotech recently licensed the gene therapy from Boston Children's Hospital and plans to bring it to low- and middle-income countries.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

The panel of four proteins, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

The panel, developed by Penn and Mayo researchers within an NCI project, is currently undergoing prospective testing to see if it can ID pancreatic cancer in patients at increased risk.

Sales rose 2 percent overall in 2025, driven by the strong performance of several oncology drugs, including greater uptake of HER2 treatment Phesgo.

UniQure had planned to seek accelerated approval for AMT-130 early 2026, but then said its plans were stalled after unexpected FDA feedback.

Medicare lab spending totaled $8.4 billion in 2024, up 5 percent year over year, with $3.6 billion of that spent on genetic testing, an increase of 20 percent over 2023.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

After a young woman develops mobility and speech issues, her grandmother seeks help from her genetic counselor, who flags a major shortcoming of the test provided to the family.

The company, founded by UC Berkeley scientists including Jennifer Doudna, is preparing to test its lead candidate STX-1150 in hypercholesterolemia.

While labs overwhelmingly welcomed the ruling, it could make it more difficult for firms that want FDA's imprimatur for LDTs to get such tests reviewed by the agency.

At the World Economic Forum, CEO Stéphane Bancel expressed concern about the US vaccine market but remained committed to cancer and rare disease mRNA programs.

Amid growing evidence suggesting circadian rhythms play a critical in the safety and efficacy of CAR T-cell therapy, researchers are calling for prospective validation.

Researchers explored why only 40 percent of patients responded to Amgen's Imdelltra using TellBio's liquid biopsy test and showed its potential as a non-invasive companion diagnostic.

Mira is bringing its version of Oxford Cancer Biomarkers' PGx test to the US in the newly launched ToxNav Advantage assay.

If the provision passes as part of the bill, it would address a major priority of many firms in the MCED business.

The company discussed plans to leverage MRD in drug development during a call to discuss Q4 and full-year 2025 financials.

All patients with autoimmune hemolytic anemia in a small study initially achieved remission, though two eventually relapsed, opening the way for more research.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in stiff person syndrome.

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this year.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying treatment and not just a seizure reducer.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in patients with gastroesophageal and pancreatic cancers.